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Objectives: Delayed-release dimethyl fumarate (DMF; also known as gastro-
resistant DMF) and fingolimod are oral disease-modifying treatments for relaps-
ing-remitting multiple sclerosis (RRMS). Direct comparisons of these agents are 
not possible due to a lack of head-to-head trials. In this study, comparative effec-
tiveness research was conducted by indirectly comparing efficacy outcomes at 2 
years with DMF or fingolimod treatment of RRMS in Phase 3 studies. MethOds: 
Individual patient data from the DEFINE and CONFIRM studies of DMF (pooled) 
and aggregate data from the FREEDOMS and FREEDOMS II studies of fingolimod 
(pooled using random effects meta-analysis) were utilised. Only results using the 
approved dosage of DMF (240 mg twice daily) and fingolimod (0.5 mg once daily) 
are reported. Matching-adjusted indirect comparison was conducted as described 
in Signorovitch et al (2010). Patients in the pooled DMF trials were weighted such 
that their average baseline characteristics (age, gender, time from onset of symp-
toms, Expanded Disability Status Scale score, number of relapses in previous year) 
matched those reported for patients in pooled fingolimod trials. After matching, 
weighted efficacy outcomes for patients treated with DMF were compared with 
summary efficacy outcomes for patients treated with fingolimod. Results: After 
matching, all baseline characteristics were balanced between the pooled DMF tri-
als and the pooled fingolimod trials. At 2 years, annualised relapse rate ratio (95% 
confidence interval [CI]) for DMF vs placebo was 0.52 (0.43, 0.62) and for fingolimod 
vs placebo was 0.48 (0.42, 0.55). Twelve-week confirmed disease progression hazard 
ratio (95% CI) for DMF vs placebo was 0.70 (0.57, 0.85) and for fingolimod vs placebo 
was 0.76 (0.61, 0.95). Additional data, including comparison of DMF vs fingolimod, 
will be presented. cOnclusiOns: In a matching-adjusted indirect comparison, the 
efficacy of DMF was similar to that of fingolimod on clinical measures of relapse 
and disability progression.
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Objectives: Relapses and disability progression are the clinical hallmarks of MS 
and the two most commonly assessed endpoints for therapeutic interventions in 
clinical trials. For many patients relapses are the initial defining feature of MS. 
However, the accumulation of disability has the greatest long-term clinical, social 
and economic impact on patients and society. This study evaluated the compara-
tive efficacy of disease-modifying therapies for multiple sclerosis and ranked 
each therapy based on probabilities of being among the best treatments for each 
outcome. MethOds: A network meta-analysis was conducted within a Bayesian 
framework to estimate comparative annualised relapse rates (ARR) and risks of 
disability progression (defined by both a 3-month, and 6-month confirmation 
interval). Cumulative ranking analysis, using the Surface Under the Cumulative 
RAnking curve (SUCRA) method, provided a ranking of treatments for each out-
come. Results: Alemtuzumab and natalizumab had the highest SUCRA scores 
for ARR (> 90%) and disability progression confirmed after three months (> 80%), 
while IFN β -1a 30mcg ranked lowest among active treatments for these outcomes. 
Ranking of treatments was affected by the definition of disability progression largely 
due to the conflicting results of IFN β -1b 250 mcg, ranking among the most effi-
cacious treatments for disability progression confirmed after six months (> 90%) 
and among the least efficacious for disability progression confirmed after three 
months (< 50%). Alemtuzumab and natalizumab both scored relatively highly for 
disability progression confirmed after six months. Notable variation in ranking 
across outcomes was observed for fingolimod (> 70% for ARR, < 50% for the disability 
progression outcomes). cOnclusiOns: The magnitude of treatment effects and 
associated uncertainty varied between DMTs, and across outcomes. While natali-
zumab and alemtuzumab demonstrated consistently high ranking for both relapse 
and progression, with older interferon-beta and glatiramer acetate products ranking 
lowest, variation in disability progression definitions lead to variation in the relative 
ranking of treatments.
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Objectives: Neuromyelitis Optica (NMO) has been described as a disease clinically 
characterised by severe optic neuritis and transverse myelitis. There are very few 
epidemiological studies in NMO and no randomised controlled studies that guide 
therapy. The aim of this review is to determine epidemiology of NMO and to provide 
an algorithm of treatment. MethOds: A systematic search was conducted of the 
relevant published evidence from Embase, MEDLINE, and Cochrane. Search limits 
were articles in English and in human. Retrieved citations were screened by two 
independent reviewers according to inclusion criteria: NMO, incidence, prevalence, 
and treatments reported in population base and observational studies. The analy-
ses of comparable outcomes were carried out as per appropriate statistics along 
with critical appraisal of the studies. Results: A total 16 studies met the inclusion 
criteria including six studies reported epidemiological data while 10 other studies 
reported treatment algorithm. Incidence of NMO ranged from 0.05 per 100,000 per 
year in United Kingdom (UK) to 0.4 per 100,000 in Southern Denmark. Prevalence 
was ranged from 0.44 per 100,000 in UK to 4.4 per 100,000 in Southern Denmark. 
Peak prevalence of NMO occurs among the people at 40-49 years of age. Low level 
evidence recommended methylprednisolone 1g/day for 3 to 5 days or 2 to 3 ses-
sions of plasmapheresis per week, up to 7 sessions for acute attacks of NMO. Nine 
studies observed the improvements in the reduction of mean annualized relapse 
rate. cOnclusiOns: There is limited evidence on current available treatment thera-
pies for NMO. The available low level evidence found that high dose intravenous 
and overseas databases including Ovid-MEDLINE, Ovid-EMBASE and Cochrane 
Library. Total of 274 studies were searched and 6 studies were included in the final 
assessment. Each of the stages from literature search and extraction of data were 
carried out independently by 2 researchers. Results: The effectiveness of CBL 
gene mutation test was assessed by CBL gene mutation detection rate, relevance 
between CBL gene mutation and clinical symptoms, and impact on medical deci-
sions. The CBL gene mutation detection rate was 5 to 19% among JMML patients. The 
hemoglobin level and age-at-diagnosis were both significantly low among patients 
with a CBL gene mutation (p= .02, p= .037). There was intent to assess the impact 
of detecting CBL gene mutation on the medical decisions such as changes in the 
treatment plan and/or method; however, there were no studies reporting on this 
matter. cOnclusiOns: There is a need for quick and accurate diagnosis for JMML, 
which is an intractable disease occurring in childhood, and the test in question 
can be helpful in deciding on stem cell transplantation. Also, considering that CBL 
gene mutation occurs exclusively from other gene mutations (PTPN11, RAS, NF1, 
etc.) causing JMML, it was deemed that even a low detection rate of 5 to 19% had a 
clinical significance. The CBL gene mutation test is an effective test that can con-
tribute to the diagnosis of JMML and help determine the treatment strategy (Grade 
of recommendation: C).
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Objectives: To compare confirmed disability improvement in propensity score 
(PS)-matched cohorts of patients receiving fingolimod or BRACE (beta-interferons 
or glatiramer acetate) following previous BRACE treatment, who had active multiple 
sclerosis (MS), using data from two German observational studies, PANGAEA and 
PEARL, respectively. MethOds: Patients with active MS (≥ 1 relapse in the year 
before the study) from the PANGAEA and PEARL registries were included if they 
had received BRACE before participating in the studies and did not have miss-
ing relapse data in the previous year. Patients from the PANGAEA registry were 
excluded if they had participated in PEARL. Patients in the PANGAEA cohort 
were matched in a 3:1 ratio to patients in the PEARL cohort using a PS-matching 
approach. Time to 3-month and 6-month confirmed disability improvement was 
assessed using a Kaplan–Meier approach. Hazard ratios for confirmed disability 
improvement (fingolimod vs BRACE) were estimated using a Cox proportional haz-
ards model. Results: After PS matching, a total of 1535 patients were included 
(PANGAEA, n= 1163; PEARL, n= 372). The proportions of patients in the PANGAEA 
and PEARL cohorts with 3-month confirmed disability improvement were 14.6% and 
7.0%, respectively (p< 0.001). Similar results were seen for 6-month confirmed dis-
ability improvement (11.0% vs 6.2%; p< 0.001). The probability of 3-month confirmed 
disability improvement was significantly higher in PANGAEA compared with PEARL 
(175% increase; HR, 2.75; 95% CI, 1.82–4.15; p< 0.001). The corresponding value for 
6-month confirmed disability improvement was a 126% increase (2.26; 1.45–3.53; 
p< 0.001). Similar findings were found in subgroups of patients with at least 1 year of 
follow-up (3-month: 176% increase; 2.76, 1.80–4.22; p< 0.001; 6-month: 136% increase; 
2.36, 1.50–3.69; p< 0.001). cOnclusiOns: This comparison of real-world cohorts 
of patients with MS demonstrates that fingolimod treatment is associated with 
statistically significant increases in the probability of confirmed disability improve-
ment compared with BRACE.
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Objectives: BG-12 and Teriflunomide are the first two oral therapeutics for the 
treatment of Multiple Sclerosis. At the moment there is no direct comparison 
of these agents. The adjusted indirect comparison is a comparison of different 
therapies adjusted according to their direct comparison results against a common 
control, so that the strength of the randomised trials is preserved. MethOds: A 
Systematic literature search was conducted in the databases of Medline, Embase 
and Cochrane. Due to a lack of direct evidence an adjusted indirect comparison 
by Bucher in efficacy endpoints was performed. The risk of bias tool was used to 
assess the methodological quality of the included studies. Results: 339 studies 
were identified in a systematic literature search. Finally four RCTs were eligible in 
which 4861 patients had been randomized. All included studies have a low risk of 
bias. There were no significant heterogeneity between the included studies in the 
operationalization of the relevant endpoints for AIC. Adjusted Indirect comparisons 
could be performed in the endpoints annual relapse rate, percentage of relapse 
free patients and percentage of patients with EDSS progression. In the annual-
ized relapse rate BG-12 gains a statistically significant 44% risk reduction against 
Laquinimod (RR= 0,66 [0,52;0,85]) and 26% against Teriflunomide (RR= 0,74 [0,56;0,99). 
In no other endpoint the results were significant. cOnclusiOns: It can be assumed 
that the relapse risk under BG-12 is less than under Laquinimod or Teriflunomide. 
The possible superiority of BG-12 has to be checked with the help of further direct 
comparative RCTs.
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